What will Ginkgo Bioworks foundry revenue be in the first quarter of 2023?
Started
Sep 15, 2022 07:00PM UTC
Closed Apr 01, 2023 03:59AM UTC
Closed Apr 01, 2023 03:59AM UTC
Scaling production of synthetic biology processes remains a key challenge (Institution of Engineering and Technology, Harvard Business Review). Gingko Bioworks foundry and codebase offers a platform to facilitate scaling both the research and production processes of their customers by programming and manufacturing cells on their behalf (Gingko Bioworks, Forbes, Nasdaq). These “cell programs” allow companies to manufacture food, pharmaceutical, and petrochemical products through biological processes (Gingko Bioworks).
This question will be resolved based on Ginkgo Bioworks’ first quarter financial report, which can be found on their investment web page. Foundry revenue for Q2 2022 can be found on slide 12 of the Q2 presentation and page 7 of the SEC filing.
Additional Resources:
Resolution Notes
Ginkgo Bioworks reported $34 million of foundry revenue (now reported as "Cell Engineering Revenue") for Q1 2023.
https://s28.q4cdn.com/823357996/files/doc_financials/2023/q1/Q1-2023-Earnings-Slides-FINAL.pdf
| Possible Answer | Correct? | Final Crowd Forecast |
|---|---|---|
| Less than $30 million | 4% | |
| More than or equal to $30 million but less than $45 million | 16% | |
| More than or equal to $45 million but less than $60 million | 55% | |
| More than or equal to $60 million but less than $75 million | 22% | |
| More than or equal to $75 million | 2% |
Crowd Forecast Profile
| Participation Level | |
|---|---|
| Number of Forecasters | 40 |
| Average for questions older than 6 months: 58 | |
| Number of Forecasts | 162 |
| Average for questions older than 6 months: 207 | |
| Accuracy | |
|---|---|
| Participants in this question vs. all forecasters | better than average |
